InMed Pharmaceuticals Inc. - Common Shares (NQ:INM)

1.330 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about InMed Pharmaceuticals Inc. - Common Shares

< Previous 1 2

...

9 10 11 12 13 14 15 16 Next >

24 Stocks Moving in Thursday's Pre-Market Session ↗

November 18, 2021

Gainers Sono Group N.V. (NASDAQ: SEV) rose 33% to $50.80 in pre-market trading. Sono Group shares climbed 155% on Wednesday after the company priced its IPO at $15 per share....

Via Benzinga

Topics Initial Public Offering

InMed Pharmaceuticals Working to Address Rare Cannabinoid Opportunities ↗

November 17, 2021

InMed Pharmaceuticals (NASDAQ:

Via Benzinga

InMed Pharmaceuticals (INM): Progress Across the Business

November 17, 2021

LONDON, UK / ACCESSWIRE / November 17, 2021 / With the recent closing of the BayMedica acquisition, InMed now has a substantially different profile than just a few months ago. The company is now in its...

From Edison Investment Research Limited

Via AccessWire

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Working on Answer to Mass Production of Rare, Otherwise Depleted Cannabinoid Opportunities

November 16, 2021

Via Investor Brand Network

Topics Cannabis

InMed Pharmaceuticals Files Patent Application for Treatment of Neurodegenerative Diseases with Rare Cannabinoid ↗

November 11, 2021

InMed Pharmaceuticals has filed an international patent application that specifies a rare cannabi...

Via Benzinga

Topics Intellectual Property

InMed Pharmaceuticals Inc. (NASDAQ: INM) Files International Patent Application for Treating Neurodegenerative Diseases Using a New Rare Cannabinoid

November 10, 2021

Via Investor Brand Network

Topics Intellectual Property

InMed Pharmaceuticals Inc. (NASDAQ: INM) Files International Patent Application for Treating Neurodegenerative Diseases Using a New Rare Cannabinoid

November 10, 2021

Via CannabisNewsWire

Topics Intellectual Property

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Financial Results, Business Updates for Q1 2022

November 10, 2021

Via Investor Brand Network

Topics Intellectual Property

InMed Pharmaceuticals Inc. Files PCT Application for Treating Neurodegenerative Disease Using Rare Cannabinoid ↗

November 03, 2021

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development, and commercialization of rare cannabinoids, today announced its filing of an international patent...

Via Benzinga

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Files PCT Application for Treating Neurodegenerative Disease Using Rare Cannabinoid

November 03, 2021

Via Investor Brand Network

Topics Intellectual Property

Successful Ginkgo Bioworks SPAC IPO Highlights Available Industry Opportunities ↗

November 02, 2021

Special purpose acquisition company Soaring Eagle Acquisition Corp. combined with Ginkgo Bioworks to form publicly-listed Ginkgo Bioworks Holdings Inc., in what is the largest-...

Via Benzinga

Topics Initial Public Offering

Successful Ginkgo Bioworks SPAC IPO Highlights Available Industry Opportunities for InMed Pharmaceuticals Inc. (NASDAQ: INM) and Synthetic Cannabinoid Production

November 01, 2021

Via Investor Brand Network

Topics Initial Public Offering

Successful Ginkgo Bioworks SPAC IPO Highlights Available Industry Opportunities for InMed Pharmaceuticals Inc. (NASDAQ: INM) and Synthetic Cannabinoid Production

November 01, 2021

Via CannabisNewsWire

Topics Initial Public Offering

55 Biggest Movers From Friday ↗

October 25, 2021

Gainers Phunware, Inc. (NASDAQ: PHUN) shares jumped 471.2% to close at $8.74 on Friday. Phunware shares jumped over 45% on Thursday, possibly in sympathy with Digital World...

Via Benzinga

35 Stocks Moving In Friday's Mid-Day Session ↗

October 22, 2021

Gainers Phunware, Inc. (NASDAQ: PHUN) rose 1099% to $18.35. Phunware shares jumped over 45% on Thursday, possibly in sympathy with Digital World Acquisition as traders circulated...

Via Benzinga

26 Stocks Moving in Friday's Pre-Market Session ↗

October 22, 2021

Gainers Phunware, Inc. (NASDAQ: PHUN) rose 300% to $6.10 in pre-market trading. Phunware shares jumped over 45% on Thursday, possibly in sympathy with Digital World Acquisition...

Via Benzinga

23 Stocks Moving in Thursday's Pre-Market Session ↗

October 21, 2021

Gainers Digital World Acquisition Corp. (NASDAQ: DWAC) rose 34.9% to $13.44 in pre-market trading after announcement of a proposed merger with Trump Media & Technology Group...

Via Benzinga

Topics Government

46 Biggest Movers From Yesterday ↗

October 19, 2021

Gainers Valneva SE (NASDAQ: VALN) shares surged 39.8% to close at $39.21 on Monday after the company reported VLA2001 met both co-primary endpoints in the Phase 3 pivotal trial...

Via Benzinga

34 Stocks Moving In Monday's Mid-Day Session ↗

October 18, 2021

Gainers Valneva SE (NASDAQ: VALN) shares jumped 34.6% to $37.75 after the company reported VLA2001 met both co-primary endpoints in the Phase 3 pivotal trial Cov-Compare....

Via Benzinga

21 Stocks Moving in Monday's Pre-Market Session ↗

October 18, 2021

Gainers Valneva SE (NASDAQ: VALN) rose 34.4% to $37.69 in pre-market trading after the company disclosed positive Phase 3 results for inactivated, adjuvanted COVID-19 vaccine...

Via Benzinga

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Completion of BayMedica Acquisition

October 14, 2021

Via Investor Brand Network

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Completion of BayMedica Acquisition

October 14, 2021

Via CannabisNewsWire

18 Stocks Moving in Thursday's Pre-Market Session ↗

October 14, 2021

Gainers TSR, Inc. (NASDAQ: TSRI) rose 40.2% to $12.89 in pre-market trading after the company reported record revenue for its first quarter. Cemtrex, Inc. (NASDAQ: CETX) rose 34....

Via Benzinga

CBDNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Poised to Become Global Leader in Manufacture of Rare Cannabinoids

October 08, 2021

Via Investor Brand Network

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Begins Phase 2 Clinical Trial Evaluating CBN in the EB Treatment

September 30, 2021

Via CannabisNewsWire

The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs ↗

October 08, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7) Alkermes plc (NASDAQ: ALKS)...

Via Benzinga

The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results ↗

October 07, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6) Enanta Pharmaceuticals, Inc...

Via Benzinga

The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal ↗

October 06, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) Bicycle Therapeutics plc (...

Via Benzinga

The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout ↗

October 05, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 4) Avadel Pharmaceuticals plc (...

Via Benzinga

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Begins Phase 2 Clinical Trial Evaluating CBN in the EB Treatment

September 30, 2021

Via Investor Brand Network

< Previous 1 2

...

9 10 11 12 13 14 15 16 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.